Literature DB >> 27789932

Idarucizumab.

.   

Abstract

Entities:  

Year:  2016        PMID： 27789932      PMCID： PMC5079781          DOI： 10.18773/austprescr.2016.076

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  2 in total

1.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

2.  Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

Authors:  Stephan Glund; Joachim Stangier; Michael Schmohl; Dietmar Gansser; Stephen Norris; Joanne van Ryn; Benjamin Lang; Steven Ramael; Viktoria Moschetti; Fredrik Gruenenfelder; Paul Reilly; Jörg Kreuzer
Journal:  Lancet       Date:  2015-06-15       Impact factor: 79.321
  2 in total
  2 in total

1.  Treating patients on new anticoagulant drugs.

Authors:  Christopher Daly
Journal:  Aust Prescr       Date:  2016-12-05

Review 2.  Long-term prescribing of new oral anticoagulants.

Authors:  Paul Kl Chin; Matthew P Doogue
Journal:  Aust Prescr       Date:  2016-12-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.